Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Therapy for acute pancreatitis with platelet-activating factor receptor antagonists Chen C; Xia SH; Chen H; Li XHWorld J Gastroenterol 2008[Aug]; 14 (30): 4735-8Acute pancreatitis (AP) causes release of platelet-activating factor (PAF), which induces systemic effects that contribute to circulatory disturbances and multiple organ failure. PAF is a cell surface secretion of bioactive lipid, which could produce physiological and pathological effects by binding to its cell surface receptor called platelet-activating factor receptor (PAF-R). Studies showed that PAF participate in the occurrence and development of AP and administration of platelet-activating factor receptor antagonists (PAF-RAs) could significantly reduce local and systemic events after AP. PAF has also been implicated as a key mediator in the progression of severe AP, which can lead to complications and unacceptably high mortality rates. Several classes of compounds show significant PAF-RAs, and significant local and systemic effects on reducing inflammatory changes. As a preventive treatment, PAF-RA could block a series of PAF-mediated inflammatory injury and thus improve the prognosis of AP. This review introduces the important role of PAF-RA in the treatment of AP.|Acute Disease[MESH]|Animals[MESH]|Anti-Inflammatory Agents/*therapeutic use[MESH]|Azepines/therapeutic use[MESH]|Ginkgolides/therapeutic use[MESH]|Humans[MESH]|Imidazoles/therapeutic use[MESH]|Lactones/therapeutic use[MESH]|Leucine/analogs & derivatives/therapeutic use[MESH]|Pancreatitis/*drug therapy/metabolism[MESH]|Platelet Aggregation Inhibitors/*therapeutic use[MESH]|Platelet Membrane Glycoproteins/*antagonists & inhibitors/metabolism[MESH]|Pyridinium Compounds/therapeutic use[MESH]|Receptors, G-Protein-Coupled/*antagonists & inhibitors/metabolism[MESH]|Tetrahydroisoquinolines/therapeutic use[MESH]|Treatment Outcome[MESH]|Triazoles/therapeutic use[MESH] |